CN1538843A - 神经营养性藤霉素类似物 - Google Patents
神经营养性藤霉素类似物 Download PDFInfo
- Publication number
- CN1538843A CN1538843A CNA018228860A CN01822886A CN1538843A CN 1538843 A CN1538843 A CN 1538843A CN A018228860 A CNA018228860 A CN A018228860A CN 01822886 A CN01822886 A CN 01822886A CN 1538843 A CN1538843 A CN 1538843A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- spinal cord
- damage
- nerve
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000508 neurotrophic effect Effects 0.000 title claims abstract description 22
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- 230000006378 damage Effects 0.000 claims abstract description 15
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 39
- 238000012360 testing method Methods 0.000 claims description 26
- 210000005036 nerve Anatomy 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 19
- 230000002093 peripheral effect Effects 0.000 claims description 15
- 208000020431 spinal cord injury Diseases 0.000 claims description 15
- 230000012010 growth Effects 0.000 claims description 13
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 12
- 230000003961 neuronal insult Effects 0.000 claims description 12
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 229940053128 nerve growth factor Drugs 0.000 claims description 11
- 230000006764 neuronal dysfunction Effects 0.000 claims description 11
- 210000000278 spinal cord Anatomy 0.000 claims description 11
- 201000001119 neuropathy Diseases 0.000 claims description 9
- 230000007823 neuropathy Effects 0.000 claims description 9
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 239000005022 packaging material Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000008929 regeneration Effects 0.000 claims description 6
- 238000011069 regeneration method Methods 0.000 claims description 6
- 206010008748 Chorea Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 241001597008 Nomeidae Species 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 239000006285 cell suspension Substances 0.000 claims description 5
- 208000012601 choreatic disease Diseases 0.000 claims description 5
- 239000007952 growth promoter Substances 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 claims description 4
- 208000000239 Hypertrophic Gastritis Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 206010027910 Mononeuritis Diseases 0.000 claims description 4
- 206010029240 Neuritis Diseases 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 206010037779 Radiculopathy Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 208000013734 mononeuritis simplex Diseases 0.000 claims description 4
- 201000005518 mononeuropathy Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000005987 polymyositis Diseases 0.000 claims description 4
- 208000019629 polyneuritis Diseases 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 230000007514 neuronal growth Effects 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims 5
- 230000008764 nerve damage Effects 0.000 claims 5
- 230000007170 pathology Effects 0.000 claims 2
- 230000007643 physiology damage Effects 0.000 claims 2
- 208000032984 Intraoperative Complications Diseases 0.000 claims 1
- 230000028600 axonogenesis Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 11
- 230000001537 neural effect Effects 0.000 abstract description 9
- 230000004064 dysfunction Effects 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 21
- YPINZEGNLULHHT-UHFFFAOYSA-N Fujimycin Natural products COC1CC(CCC1O)C=C(/C)C2OC(=O)C3CCCCCN3C(=O)C(=O)C4(O)OC(C(CC4C)OC)C(OC)C(C)CC(=CC(CC=C)C(=O)CC(O)C2C)C YPINZEGNLULHHT-UHFFFAOYSA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 229960001967 tacrolimus Drugs 0.000 description 19
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 19
- 239000002609 medium Substances 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 210000002241 neurite Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003497 sciatic nerve Anatomy 0.000 description 5
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 4
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000004295 hippocampal neuron Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- -1 dimethyl sulfoxine Chemical compound 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 101001104083 Homo sapiens Rabphilin-3A Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001738 Nervous System Trauma Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 description 2
- 102100040040 Rabphilin-3A Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 208000028412 nervous system injury Diseases 0.000 description 2
- 210000003757 neuroblast Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000463219 Epitheca Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 102000012547 Olfactory receptors Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010039670 Sciatic nerve injury Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Packages (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
神经突长度(μm) | |
未处理组 | 372.3±18.23 |
藤霉素组(10nM) | 423.4±19.50 |
化合物(Ia)组(10nM) | 502.2±23.61* |
神经突长度(μm) | |
NT | 94.75±3.734 |
NGF(10ng/ml) | 198.8±8.991 |
藤霉素(10nM)+NGF(10ng/ml) | 227.6±9.130* |
化合物(Ia)(1nM)+NGF(10ng/ml) | 256.0±9.067* |
功能的分数 | |||
介质(s.c.)(含30%DMSO的盐水) | 化合物(Ia) | ||
1mg/kg(s.c.) | 5mg/kg(s.c.) | ||
第15天 | 1.67±0.08 | 2.58±0.17* | 3.17±0.08* |
第16天 | 1.83±0.08 | 2.83±0.17* | 3.50±0.00* |
第17天 | 2.50±0.00 | 3.08±0.22* | 3.50±0.00* |
介质(s.c.)(含有30%DMSO的盐水) | 化合物(Ia) | ||
1mg/kg(s.c.) | 5mg/kg(s.c.) | ||
再生的有髓鞘的轴突 | 5.5±2.7 | 19±2.4* | 20±2.9* |
改进的Tarlov/Klinger分数 | ||
介质(s.c.)(包含30%DMSO的盐水) | 化合物(Ia)2mg/kg(s.c.) | |
第2星期 | 2.1±0.1 | 3.7±0.2* |
横梁行走分数 | ||
介质(s.c.)(包含30%DMSO的盐水) | 化合物(Ia)2mg/kg(s.c.) | |
第2星期 | 0.9±0.1 | 2.0±0.3* |
脚印分数 | ||
介质(s.c.)(包含30%DMSO的盐水) | 化合物(Ia)2mg/kg(s.c.) | |
第2星期 | 1.7±0.4 | 3.6±0.3* |
FKBP12结合IC50(nM) | MLR IC50(nM) | |
化合物(Ia) | <5 | >100 |
藤霉素 | <5 | <2 |
Claims (42)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25850000P | 2000-12-29 | 2000-12-29 | |
US60/258,500 | 2000-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1538843A true CN1538843A (zh) | 2004-10-20 |
CN1293877C CN1293877C (zh) | 2007-01-10 |
Family
ID=22980816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018228860A Expired - Fee Related CN1293877C (zh) | 2000-12-29 | 2001-12-31 | 神经营养性藤霉素类似物 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1353671A4 (zh) |
JP (1) | JP2004527472A (zh) |
KR (2) | KR100794204B1 (zh) |
CN (1) | CN1293877C (zh) |
AR (1) | AR035411A1 (zh) |
AU (1) | AU2002231277B2 (zh) |
BR (1) | BR0116762A (zh) |
CA (1) | CA2433384A1 (zh) |
CZ (1) | CZ20032060A3 (zh) |
HU (1) | HUP0302521A3 (zh) |
IL (1) | IL156664A0 (zh) |
MX (1) | MXPA03005941A (zh) |
NO (1) | NO20032913D0 (zh) |
NZ (1) | NZ527209A (zh) |
PL (1) | PL366301A1 (zh) |
RU (1) | RU2288716C2 (zh) |
WO (1) | WO2002053159A1 (zh) |
ZA (1) | ZA200305806B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003901023A0 (en) * | 2003-03-04 | 2003-03-20 | Fujisawa Pharmaceutical Co., Ltd. | New use |
JP2007518692A (ja) * | 2004-01-20 | 2007-07-12 | アステラス製薬株式会社 | 勃起不全治療方法 |
EP1810675A1 (en) * | 2006-01-18 | 2007-07-25 | Institut Curie | Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
JP2009102226A (ja) * | 2006-02-14 | 2009-05-14 | Meiji Milk Prod Co Ltd | 脊髄損傷治療剤 |
CA2730751A1 (en) * | 2008-07-23 | 2010-01-28 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
EP2817009A1 (en) * | 2012-02-23 | 2014-12-31 | INSERM - Institut National de la Santé et de la Recherche Médicale | Calcineurin inhibitors for use in the treatment of lesional vestibular disorders |
GB201309375D0 (en) * | 2013-05-24 | 2013-07-10 | Chronos Therapeutics Ltd | Medical methods and compounds for medical use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2799208B2 (ja) * | 1987-12-09 | 1998-09-17 | フアイソンズ・ピーエルシー | マクロ環状化合物 |
GR1001225B (el) * | 1989-09-14 | 1993-06-30 | Fisons Plc | Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους. |
US5541193A (en) | 1991-09-05 | 1996-07-30 | Abbott Laboratories | Heterocycle-containing macrocyclic immunomodulators |
GB9202196D0 (en) * | 1992-02-01 | 1992-03-18 | Fisons Plc | Method of treatment |
GB9218027D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
GB9917158D0 (en) * | 1999-07-21 | 1999-09-22 | Fujisawa Pharmaceutical Co | New use |
-
2001
- 2001-12-27 AR ARP010106058A patent/AR035411A1/es unknown
- 2001-12-31 CA CA002433384A patent/CA2433384A1/en not_active Abandoned
- 2001-12-31 NZ NZ527209A patent/NZ527209A/en unknown
- 2001-12-31 MX MXPA03005941A patent/MXPA03005941A/es active IP Right Grant
- 2001-12-31 WO PCT/US2001/050419 patent/WO2002053159A1/en active IP Right Grant
- 2001-12-31 CZ CZ20032060A patent/CZ20032060A3/cs unknown
- 2001-12-31 CN CNB018228860A patent/CN1293877C/zh not_active Expired - Fee Related
- 2001-12-31 KR KR1020037008787A patent/KR100794204B1/ko not_active IP Right Cessation
- 2001-12-31 HU HU0302521A patent/HUP0302521A3/hu unknown
- 2001-12-31 EP EP01991558A patent/EP1353671A4/en not_active Withdrawn
- 2001-12-31 RU RU2003123493/15A patent/RU2288716C2/ru not_active IP Right Cessation
- 2001-12-31 BR BR0116762-6A patent/BR0116762A/pt not_active Application Discontinuation
- 2001-12-31 PL PL01366301A patent/PL366301A1/xx not_active Application Discontinuation
- 2001-12-31 AU AU2002231277A patent/AU2002231277B2/en not_active Ceased
- 2001-12-31 KR KR1020077003889A patent/KR20070030331A/ko not_active Application Discontinuation
- 2001-12-31 JP JP2002554109A patent/JP2004527472A/ja not_active Ceased
- 2001-12-31 IL IL15666401A patent/IL156664A0/xx unknown
-
2003
- 2003-06-24 NO NO20032913A patent/NO20032913D0/no not_active Application Discontinuation
- 2003-07-28 ZA ZA2003/05806A patent/ZA200305806B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1353671A1 (en) | 2003-10-22 |
KR100794204B1 (ko) | 2008-01-14 |
CA2433384A1 (en) | 2002-07-11 |
NO20032913D0 (no) | 2003-06-24 |
AR035411A1 (es) | 2004-05-26 |
HUP0302521A3 (en) | 2007-03-28 |
AU2002231277B2 (en) | 2006-11-30 |
KR20070030331A (ko) | 2007-03-15 |
JP2004527472A (ja) | 2004-09-09 |
ZA200305806B (en) | 2005-01-26 |
EP1353671A4 (en) | 2004-07-14 |
NZ527209A (en) | 2005-09-30 |
CN1293877C (zh) | 2007-01-10 |
RU2288716C2 (ru) | 2006-12-10 |
HUP0302521A2 (hu) | 2003-11-28 |
RU2003123493A (ru) | 2005-01-20 |
MXPA03005941A (es) | 2005-02-14 |
CZ20032060A3 (cs) | 2004-01-14 |
KR20040007431A (ko) | 2004-01-24 |
IL156664A0 (en) | 2004-01-04 |
PL366301A1 (en) | 2005-01-24 |
WO2002053159A1 (en) | 2002-07-11 |
BR0116762A (pt) | 2004-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yin et al. | Taxol-modified collagen scaffold implantation promotes functional recovery after long-distance spinal cord complete transection in canines | |
CN1732011A (zh) | 中枢神经系统损伤的治疗方法 | |
EA015644B1 (ru) | Способ лечения заболеваний хряща | |
Schenk et al. | Interactions between caffeine and cocaine in tests of self-administration | |
CN1293877C (zh) | 神经营养性藤霉素类似物 | |
RU2096044C1 (ru) | Ветеринарный имплантируемый препарат для регулирования биологического ритма животных | |
CN1252722A (zh) | 脱羰乙氧氯雷他定在治疗尿失禁、晕动病和眩晕药剂的制备中的应用 | |
CN1794999A (zh) | 神经损伤治疗剂 | |
CN1723034A (zh) | 治疗糖尿病的组合物和方法 | |
MXPA02007095A (es) | Combinacion de farmacos para el tratamiento de la depresion y desordenes relacionados que comprenden mirtazapina. | |
CN1292749C (zh) | 2-[5-(4-氟苯基)-3-吡啶基甲氨基甲基]苯并二氢吡喃及其生理学上可接受的盐的新用途 | |
AU2002231277A1 (en) | Neurotrophic tacrolimus analogs | |
CN105189449A (zh) | 非肽bdnf神经营养蛋白模拟物 | |
CN105209427A (zh) | 非肽bdnf神经营养蛋白模拟物 | |
JP2009504636A (ja) | 血漿または血清を含む神経損傷治療用の医薬組成物 | |
US20040077676A1 (en) | Neurotrophic tacrolimus analogs | |
RU2351021C1 (ru) | Способ моделирования экспериментального ревматоидного артрита | |
Mavrogianni et al. | Safety and reproductive safety of moxidectin in goats | |
Hasan et al. | The short-acting anesthetic propofol produces biphasic effects—depression and withdrawal rebound overshoot—on some (but not all) limbic evoked potentials in the behaving rat | |
Bloom et al. | Behavioral effects of chronic melatonin and pregnenolone injections in a myelin mutant rat (taiep) | |
EP3362059B1 (en) | New combination therapies for treating neurological damage | |
CN104257658B (zh) | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 | |
CN1269720A (zh) | 增加骨容量的方法 | |
US6852496B1 (en) | Methods of screening for agents that promote nerve cell growth | |
CN1883491A (zh) | 人参皂苷Rh1的医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ASTELLAS PHARMA INC. Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD. Effective date: 20060428 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060428 Address after: Tokyo, Japan Applicant after: Yamanouchi Pharma Co., Ltd. Address before: Osaka City, Osaka of Japan Applicant before: Fujisawa Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070110 Termination date: 20100201 |